

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PATENT COOPERATION TREATY

BEST AVAILABLE COPY
PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

NILSSON, Brita
Stockholms Patentbyrå Zacco AB
Box 23101
S-104 35 Stockholm
SUÈDE

RECEIVED

AUG 03 2001

TECH CENTER 1600/29

Date of mailing (day/month/year) 14 June 2001 (14.06.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 192966301	
International application No. PCT/SE99/02306	International filing date (day/month/year) 09 December 1999 (09.12.99)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

ACTIVE BIOTECH AB
Box 724
S-220 01 Lund
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

SBL VACCIN AB
Lundagatan 2
S-105 21 Stockholm
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☐ the International Preliminary Examining Authority ☐ other:
The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

F. Baechler

Telephone No.: (41-22) 338.83.38

NOT AVAILABLE COPY

PCT

**NOTIFICATION OF THE RECORDING
OF A CHANGE**

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

NILSSON, Brita
Stockholms Patentbyrå Zacco AB
Box 23101
S-104 35 Stockholm
SUÈDE

Date of mailing (day/month/year) 18 April 2001 (18.04.01)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 192966301	
International application No. PCT/SE99/02306	International filing date (day/month/year) 09 December 1999 (09.12.99)

1. The following indications appeared on record concerning: <input checked="" type="checkbox"/> the applicant <input type="checkbox"/> the inventor <input type="checkbox"/> the agent <input type="checkbox"/> the common representative		
Name and Address SBL VACCIN AB Lundagatan 2 S-105 21 Stockholm Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: <input checked="" type="checkbox"/> the person <input type="checkbox"/> the name <input type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence		
Name and Address ACTIVE BIOTECH AB Box 724 S-220 01 Lund Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to: <input checked="" type="checkbox"/> the receiving Office <input type="checkbox"/> the designated Offices concerned <input type="checkbox"/> the International Searching Authority <input checked="" type="checkbox"/> the elected Offices concerned <input type="checkbox"/> the International Preliminary Examining Authority <input type="checkbox"/> other:		

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer C. Cupello Telephone No.: (41-22) 338.83.38
--	---

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 13 September 2000 (13.09.00)	Applicant's or agent's file reference 192966301
International application No. PCT/SE99/02306	Priority date (day/month/year) 18 December 1998 (18.12.98)
International filing date (day/month/year) 09 December 1999 (09.12.99)	
Applicant CARLIN, Nils et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
11 July 2000 (11.07.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer Charlotte ENGER</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	---

BEST AVAILABLE COPY



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/108	A1	(11) International Publication Number: WO 00/37106 (43) International Publication Date: 29 June 2000 (29.06.00)
(21) International Application Number: PCT/SE99/02306 (22) International Filing Date: 9 December 1999 (09.12.99) (30) Priority Data: 9804415-9 18 December 1998 (18.12.98) SE (71) Applicant (for all designated States except US): SBL VACCIN AB [SE/SE]; Lundagatan 2, S-105 21 Stockholm (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): CARLIN, Nils [SE/SE]; Stallknektsgård 14, S-165 57 Hässelby (SE). ASKELÖF, Per [SE/SE]; Aspvägen 1A, S-191 41 Sollentuna (SE). BJARE, Ulf [SE/SE]; Nödhärsvägen 80, S-757 57 Uppsala (SE). (74) Agents: NILSSON, Brita et al.; AB Stockholms Patentbyrå, Zacco & Bruhn, Box 23101, S-104 35 Stockholm (SE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ORAL VACCINE AGAINST DIARRHEA (57) Abstract <p>An oral vaccine composition against enterotoxigenic <i>E. coli</i> caused diarrhea in humans is disclosed. It comprises a defined amount of at least three different types of colonization factor antigens (CFAs), e.g. 100 to 300 µg of each type, selected from the group consisting of CFA I, CFA II (CS1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6), on killed <i>E. coli</i> bacteria lacking the gene encoding the heat labile enterotoxin (LT⁻), together with a defined amount of the B-subunit of cholera toxin (CTB), e.g. 0.5–2.0 mg, and a vehicle, such as PBS, which vaccine composition is purified from possible heat stable enterotoxin (ST).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Oral vaccine against diarrhea

The present invention relates to an oral vaccine against diarrhea. More precisely, it relates to an oral vaccine composition against enterotoxigenic *E.coli* caused diarrhea in humans.

Background

Bacteria and viruses often express on or within their membrane, proteins which in a certain environment function as a support for the organism to associate in a specific way or adhere to a surface. Such a surface may be the inner wall of the gastrointestinal tract, the oesophagus or any other biological surface or membrane in a human or animal body, where an organism may find an optimal environment for growth. Microbial membrane proteins of this kind are often named colonization factor antigens (CFA) or fimbriae. In the literature, other words such as pili, hemagglutinins, filamentous or fibrillar proteins are used for the same kind of substances. For convenience, "CFA" will be used herein to cover all these kinds of membrane proteins which also may have an antigenic character. For most organisms the production of their CFAs is controlled by various factors in the environment, which in turn may activate regulatory genes in the plasmid DNA.

A number of bacteria which are of medical interest have been shown to produce CFAs associated with their membrane. Among these, the ones which are most important for humans, are organisms which colonize the human gastrointestinal tract and the respiratory airways. Examples of organisms which colonize the gastrointestinal tract are enterotoxigenic *Escherichia coli*, *Vibrio cholerae*, *Helicobacter pylori*, *Campylobacter*, *Shigellae*, *Salmonellae* and *Yersinia*.

Of particular medical interest is the enterotoxigenic *Escherichia coli* (ETEC), since it is one of the major causes of travelers diarrhea and diarrhea among children in the developing countries and accounts for more than 1 billion diarrhea episodes and at least one million deaths per year, primarily among children.

Enterotoxigenic *E. coli* are characterized in that they produce heat labile enterotoxin (LT) and/or heat stable enterotoxin (ST).

In WO 92/14487 a method for production and use of an oral ETEC vaccine is disclosed. The ETEC bacteria with CFAs and their subcomponents (CS-antigens) are grown under specified conditions. The subsequently formalin killed bacteria may then be used as an oral vaccine against the ETEC bacteria. The CFA and CS antigens will thus function as antigens in the immunological processing that will take place in the intestine.

There were problems with the scaling up of the production of ETEC bacteria having CFAs, and a solution to the problems were disclosed in the International Patent Application WO 95/33825.

Formulations of ETEC vaccines containing the B-subunit of cholera toxin, which is antigenically similar to the heat labile enterotoxin of ETEC, and colonization factor antigens of ETEC, were shown to stimulate relevant mucosal immune responses in Swedish volunteers. (Jertborn M., et al, Vaccine, 1997; 16:255-260).

For product safety and efficacy a vaccine composition must be non-infectious and contain defined amounts of active ingredients which are the same from batch to batch.

10 **Description of the invention**

The present invention provides a new vaccine composition which is based on LT-negative killed enterotoxigenic *E. coli* bacteria comprising defined amounts of at least three different types of colonization factor antigens, and the B-subunit of cholera toxin (CTB) which is antigenically similar to the heat labile enterotoxin of ETEC. Further, the vaccine composition is purified from possible heat stable enterotoxin (ST).

The LT- negative ETEC bacteria are either laboratory selected from naturally genetically modified strains or produced by recombinant techniques.

Possibly present heat stable enterotoxin, which is a comparatively small protein of 19 amino acid residues, is washed away during the down stream processing of the vaccine composition.

The elimination of the possibility of the bacteria to produce heat label enterotoxin and removal of the possibly present the heat stable enterotoxin adds to product safety.

The killing of the bacteria should be performed in such a way that the colonization factor antigens are substantially retained, e.g. by mild formalin inactivation.

Thus, the present invention provides an oral vaccine composition against enterotoxigenic *E. coli* caused diarrhea in humans, which comprises a defined amount of at least three different types of colonization factor antigens (CFAs) selected from the group consisting of CFA I, CFA II (CS 1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6), on killed *E. coli* bacteria lacking the gene encoding the heat labile (LT) enterotoxin, together with a defined amount of the B-subunit of cholera toxin (CTB), and an vehicle, which vaccine composition is purified from possible heat stable enterotoxin (ST).

In an embodiment of the oral vaccine of the invention the defined amount of different types of CFAs is for each type of CFA at least 100 µg, and the defined amount of CTB is at least 0.5 mg, and the vehicle is a physiologically acceptable buffer solution.

In a preferred embodiment the defined amount of different types of CFAs is for each type of CFA 100 to 300 µg, and the defined amount of CTB is 0.5 to 2.0 mg.

In a most preferred embodiment of the invention the defined amount of different types of CFAs are 200 µg of CFA/I, 200 µg of CS1, 150 µg of CS2, 200 µg of CS4 and 150 µg of CS5, and 1.0 mg of CTB, and the physiologically acceptable buffer solution is phosphate buffered saline solution.

A dose of the vaccine composition will contain approximately 10^{11} bacteria.

The vaccine composition is administered to person as a drink in a glass of water containing carbonate buffer, such as sodium hydrogen carbonate.

10 Experiments

Determination of the amounts of the different colonization factor antigens

E. coli fimbriae antigens are detected by using an inhibition ELISA substantially as described by Lopez-Vidal Y., et al in the Journal of Clinical Microbiology, vol 26, 1967-1972 (1988). Briefly, the bacterial sample to be analyzed is incubated together with a fixed amount of monoclonal antibody directed against the CFA. After incubation the mixture is transferred to a plate previously coated with CFA, where residual monoclonal antibody can bind to the CFA. Bound antibody is visualized by adding horseradish peroxidase conjugated anti-mouse immunoglobulin. As substrate, o-phenylenediaminedihydrochloride in a citrate buffer is used. The optical density is measured at 450 nm in a spectrophotometer connected to a computer equipped with a data reduction software. The optical density observed is inversely proportional to the concentration of antibody in the sample.

Formulation of the vaccine composition

Lot of formulated oral ETEC Vaccine derived from monovalent bulks of formalin killed CFA/I SBL strain 101, CS1 SBL strain 106, CS2 SBL strain 107, CS4 SBL strain 104, CS5 SBL strain 105 respectively and monovalent bulk of purified rCTB.

Composition

Names of Ingredients	Unit	Function
Active substances:		
1. Monovalent Bulk: <i>E.coli</i> , CFA/I SBL-101, Formalin Killed	$2.0 \times 10^2 \mu\text{g}$ fimbriae	To elicit immune response against ETEC bacteria
2. Monovalent Bulk: <i>E.coli</i> , CS1 SBL-106, Formalin Killed	$2.0 \times 10^2 \mu\text{g}$ fimbriae	
3. Monovalent Bulk: <i>E.coli</i> , CS2 SBL-107, Formalin Killed	$1.5 \times 10^2 \mu\text{g}$ fimbriae	
4. Monovalent Bulk: <i>E.coli</i> , CS4 SBL-104, Formalin Killed	$2.0 \times 10^2 \mu\text{g}$ fimbriae	
5. Monovalent Bulk: <i>E.coli</i> , CS5 SBL-105, Formalin Killed	$1.5 \times 10^2 \mu\text{g}$ fimbriae	
6. Monovalent Bulk: rCTB, Purified	1.0 mg	
Vehicle:		
7. PBS(WHO) Buffer, pH 7.2-7.4	q.s. ad 6.0 ml	Buffer

The strains SBL-104 and SBL-105 also produced CS 6, but the amount thereof was not established. The strain SBL-107 also produced CS3, but the amount thereof was not established.

Pilot study evaluating the efficacy and reactogenicity of the oral ETEC B-subunit-killed whole cell vaccine of the invention against travelers diarrhea

In a double blind, randomized, placebo controlled pilot study three groups of Austrian travelers were investigated. In addition to the ETEC vaccine an oral B-subunit whole cell cholera vaccine was also included, since it had previously been shown in both Bangladesh (Clemens J., et al, J Infect Dis, 1988, 158:372-377) and in Finnish travelers to Morocco (Peltola H., et al Lancet, 1991, 338:1285-89) to afford significant protection against *E.coli* LT-diarrhea.

A total of 250 volunteers, adults and children, who had signed up for a trip to tropical or subtropical destinations (44 different countries in Africa, Asia and Latin-America) with a duration of stay intended to last 7 to 23 days, were included. Twelve of these were withdrawn due to violation of protocol, so that the intent to treat population encompassed 238 persons and the per protocol population, which perfectly fulfilled all the requirements, comprised 187

travelers. Two consecutive doses of vaccine or placebo were given, at an interval of 7-21 days, not less than 7 days and not more than 30 days before departure. Post vaccination symptoms and adverse events were reported after both doses. All volunteers enrolled in the study were equipped with a daily record diary to monitor episodes of travelers' diarrhea during their stay abroad and with transport media (Portagerm and Cary Blair tubes) for collection of stool samples in case of diarrhea. Travelers were instructed to hand over their travel diary, and transport media tubes immediately after return. Blood samples for testing immunogenicity were taken from a subset of 73 volunteers before and after the first and second dose of the vaccines or placebo. The post first dose sample was collected immediately before intake of the second dose, and the post second dose blood sample was drawn after return.

The formulations given to the three randomized groups of travelers were: ETEC vaccine., containing 1 mg of recombinant B-subunit of cholera toxin plus 10^{11} formalin killed ETEC bacteria of five ETEC strains expressing the most common colonization factor antigens (CFA's) such as CFA I, CFA II (CS 1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6); a B-subunit cholera whole cell vaccine (registered in Sweden since 1992), containing 1 mg recombinant subunit B cholera toxin and 10^{11} killed whole cells (Inaba, Ogawa, classical and El Tor); placebo containing 10^{11} killed *E.coli* K12. The formulations were suspended in 4 ml buffer and each dose of vaccine or placebo was given as a drink in 150 cc of a sodium hydrogen carbonate solution. Isolation and characterization of ETEC bacteria and the anti-CTB IgA ELISA were performed as described (Jertborn M., et al *ibid*).

250 volunteers received one dose of vaccine or placebo, of whom 246 also received the second dose. The study protocol was approved by the local. Ethics Committee before start of the study. Written informed consents of the volunteers were obtained before randomization.

Reactogenicity results are as follows: In total 43 volunteers (17%) had mild to moderate gastrointestinal or general symptoms after the first dose; 13 (16%) in the placebo, 13 (16%) in the cholera vaccine group and 17 (20%) in the ETEC vaccine group. After the second dose 20 (8%) had symptoms; 6 (7%) in the placebo, 7 (9%) in the cholera vaccine group and 7 (8%) in the ETEC vaccine group. Statistically, there were no differences in the proportion of volunteers reporting symptoms between the study groups.

Evaluating the efficacy of the vaccines, a case of ETEC diarrhea was defined as having three or more liquid stools, and ETEC, but no other pathogens, detected in pretreatment stools. In the Per Protocol population the incidence of ETEC was 8%(5 cases) in

the placebo group, 10%(6 cases) in the cholera vaccine group and 2% (1 case) in the ETEC vaccine group. The vaccine efficacy as regards ETEC vaccine versus placebo was 79% ($p=0.119$) and versus cholera vaccine 84% ($p=0.0496$). Comparison of ETEC diarrhea rates was done by one-sided Fisher's exact test.

5 All ETEC isolates in the Per Protocol population expressed colonization factors included in the vaccine.

The cholera vaccine gave no detectable protection against ETEC as compared with the placebo group, but it is noteworthy that only two of the ETEC cases in the cholera vaccine group were caused by bacteria producing solely the heat-labile enterotoxin (LT) against which
10 the cholera vaccine (through its B-subunit) can theoretically work.

Thus, due to the fact that there were almost exclusively LT-negative strains present in this group, the cholera vaccine is not supposed to have any effect.

Despite these results it must be kept in mind that the stool sample handling as described might be a source of error. When using transport media, there is a risk of losing
15 sensitive pathogens, whereas less sensitive ones such as *E. coli* bacteria survive, resulting in false positive cases of ETEC diarrhea (see definition of ETEC diarrhea). Hence, the proportion of ETEC diarrhea might have been overestimated. However, it is unlikely that possible false positive cases are unevenly distributed over the study groups.

Concerning immunogenicity, a significant increase in antibodies against the B-subunit
20 of cholera toxin (CTB) could be shown by means of anti-CTB IgA ELISA in the group receiving the ETEC vaccine (geometric mean titres pre- vs. post-vaccination: 7.8 vs. 58.7 after the first and 62.6 after the second dose; seroconversion after 2nd dose: 91%) and in the group receiving, the cholera vaccine (7.6 vs. 54.6 after the first and 60.1 after the second dose; seroconversion 100%). The placebo group did not show any significant increase in the anti--
25 CTB response (7.9 vs. 8.3 after the first and 11.8 after the second dose; seroconversion 29%).

Thus - although the CTB-cholera WC vaccine induced a very good response against the B-subunit - a significant influence of this vaccine on ETEC diarrhea was not observed. This could predominantly be ascribed to the fact that a majority of the ETEC strains isolated from these volunteers were only producing ST (9 from 12) and hence could not be prevented
30 by the cholera vaccine. Apparently, anti-CFA antibodies are highly important for protection against in particular diarrhea caused by ST-only ETEC.

The present results are the first to lend support in humans for the working hypothesis that oral ETEC vaccine induced anti-CFA/CS immunity can protect against diarrhea caused by ST-only producing ETEC.

Claims

1. Oral vaccine composition against enterotoxigenic *E.coli* caused diarrhea in humans, which comprises a defined amount of at least three different types of colonization factor antigens (CFAs) selected from the group consisting of CFA I, CFA II (CS 1, CS2 and CS3) and CFA IV (CS4, CS5 and CS6), on killed *E. coli* bacteria lacking the gene encoding the heat labile (LT) enterotoxin, together with a defined amount of the B-subunit of cholera toxin (CTB), and an vehicle, which vaccine composition is purified from possible heat stable enterotoxin (ST).

2. Oral vaccine according to claim 1, wherein the defined amount of different types of CFAs is for each type of CFA at least 100 µg, and the defined amount of CTB is at least 0.5 mg, and the vehicle is a physiologically acceptable buffer solution.

3. Oral vaccine according to claim 2, wherein the defined amount of different types of CFAs is for each type of CFA 100 to 300 µg, and the defined amount of CTB is 0.5 to 2.0 mg.

4. Oral vaccine according to claim 3, wherein the defined amount of different types of CFAs are 200 µg of CFA/I, 200 µg of CS1, 150 µg of CS2, 200 µg of CS4 and 150 µg of CS5, and 1.0 mg of CTB, and the physiologically acceptable buffer solution is phosphate buffered saline solution.

1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/02306

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/108

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9214487 A1 (HOLMGREN, JAN), 3 Sept 1992 (03.09.92), page 15, line 11 - line 25, Table 1 -- -----	1-4

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

- | | |
|---|--|
| <ul style="list-style-type: none"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed | <ul style="list-style-type: none"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family |
|---|--|

Date of the actual completion of the international search

22 March 2000

Date of mailing of the international search report

20 -04- 2000

Name and mailing address of the ISA
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson / MR
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/SE 99/02306

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9214487 A1	03/09/92	AT 170755 T	15/09/98
		AU 663864 B	26/10/95
		AU 1330892 A	15/09/92
		BG 61683 B	31/03/98
		BG 98070 A	30/06/94
		BR 9205677 A	17/05/94
		CA 2104877 A	27/08/92
		CZ 281556 B	13/11/96
		CZ 9301742 A	13/04/94
		DE 69226944 D,T	11/02/99
		EP 0573527 A,B	15/12/93
		SE 0573527 T3	
		ES 2123550 T	16/01/99
		FI 100391 B	00/00/00
		FI 930881 A	26/02/93
		FI 933728 A	25/10/93
		HU 67198 A	28/02/95
		HU 213924 B	28/11/97
		JP 6505730 T	30/06/94
		NO 933037 A	25/08/93
		OA 9865 A	15/08/94
		RO 109819 A	30/06/95
		SE 9100556 D	00/00/00
		SK 91093 A	11/05/94
		US 5368119 A	29/11/94

Applicant's or agent's file reference 192966301/BN	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE99/02306	International filing date (day/month/year) 09.12.1999	Priority date (day/month/year) 18.12.1998
International Patent Classification (IPC) or national classification and IPC ₇ A 61 K 39/108		
Applicant SBL Vaccin AB et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 11.07.2000	Date of completion of this report 09.01.2000
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer Patrick Andersson/EÖ Telephone No. 08-782 25 00

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/02306

I. Basis of the report

1. With regard to the **elements** of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the claims:
 pages _____, as originally filed
 pages _____, as amended (together with any statement) under article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the drawings:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
 pages _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheet/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/02306

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	<u>1-4</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-4</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-4</u>	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The claimed invention relates to an oral vaccine on killed E. coli bacteria lacking the gene encoding the heat labile (LT) enterotoxin against enterogenic E. coli caused diarrhea. The vaccine comprises at least three different types of colonization factor antigens (CFA) selected from the group consisting of CFA I, CFAII (CS 1, CS2 and CS 3) and CFA IV (CS 4, CS5 and CS6), together with B-subunit of cholera toxin and is purified from heat stable enterotoxin (ST).

The search report discloses WO9214487 (D1).

D1 discloses an oral vaccine comprising CFAs and CS-antigens. D1 does not use killed LT-negative E. coli and is therefore regarded as the general state of the art of no particular relevance.

The invention according to claims 1-4 is novel, industrially applicable and considered to involve an inventive step.

INTERNATIONAL SEARCH REPORT

1

International application No.

PCT/SE 99/02306

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 39/108

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9214487 A1 (HOLMGREN, JAN), 3 Sept 1992 (03.09.92), page 15, line 11 - line 25, Table 1 -----	1-4

☐

Further documents are listed in the continuation of Box C.

☒

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 2000

Date of mailing of the international search report

20-04-2000

Name and mailing address of the ISA

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Patrick Andersson / MR

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/12/99

International application No.
PCT/SE 99/02306

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9214487 A1	03/09/92	AT 170755 T	15/09/98
		AU 663864 B	26/10/95
		AU 1330892 A	15/09/92
		BG 61683 B	31/03/98
		BG 98070 A	30/06/94
		BR 9205677 A	17/05/94
		CA 2104877 A	27/08/92
		CZ 281556 B	13/11/96
		CZ 9301742 A	13/04/94
		DE 69226944 D,T	11/02/99
		EP 0573527 A,B	15/12/93
		SE 0573527 T3	
		ES 2123550 T	16/01/99
		FI 100391 B	00/00/00
		FI 930881 A	26/02/93
		FI 933728 A	25/10/93
		HU 67198 A	28/02/95
		HU 213924 B	28/11/97
		JP 6505730 T	30/06/94
		NO 933037 A	25/08/93
		OA 9865 A	15/08/94
		RO 109819 A	30/06/95
		SE 9100556 D	00/00/00
		SK 91093 A	11/05/94
		US 5368119 A	29/11/94